XML 11 R2.htm IDEA: XBRL DOCUMENT
v3.25.1

Pay vs Performance Disclosure - USD ($) | 4 Months Ended | 5 Months Ended | 12 Months Ended | 27 Months Ended
--- | --- | --- | --- | ---
Dec. 31, 2024 | Aug. 29, 2024 | Dec. 31, 2024 | Dec. 31, 2023 | Dec. 31, 2022 | Apr. 03, 2024
Pay vs Performance Disclosure |  |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure, Table |  |  |  | Pay Versus Performance Our Compensation Committee approves and administers our executive compensation program to align executive compensation with stockholder interests by linking pay to performance. Our overall compensation program includes a mix of short-term and long-term components through our annual cash incentive plan and our equity incentive awards. As required by Item 402(v) of Regulation S-K, we are providing the following information about the relationship between the compensation actually paid to our named executive officers and certain aspects of our financial performance. We are a smaller reporting company pursuant to Rule 405 of the Securities Act and, as such, are only required to include information for the past three fiscal years in the table below. Pay Versus Performance Table
Year |  | Summary Compensation Table Total for Mr. Bristow ($)(1) |  | Summary Compensation Table Total for Mr. Keuer ($)(1) |  | Summary Compensation Table Total for Dr. Klein ($)(1) |  | Compensation Actually Paid to Dr. Bristow ($)(3) |  | Compensation Actually Paid to Mr. Keuer ($)(3) |  | Compensation Actually Paid to Dr. Klein ($)(3) |  | Average Summary Compensation Table Total for Non-PEO NEOs ($)(2) |  | Average Compensation Actually Paid to Non-PEO NEOs ($)(3) |  | Total Stockholder Return Based on Initial Fixed $100 Investment ($)(4) |  | Net Income ($ in thousands)(5)
2024 |  | 510,416 |  | 853,520 |  | 520,911 |  | 518,016 |  | 848,453 |  | 44,698,284 |  | 461,678 |  | 3,718,227 |  | 109.89 |  | (83,724 | )
2023 |  | 358,800 |  | N/A |  | N/A |  | 290,864 |  | N/A |  | N/A |  | 361,937 |  | 323,666 |  | 79.07 |  | (5,339 | )
2022 |  | 358,800 |  | N/A |  | N/A |  | 523,780 |  | N/A |  | N/A |  | 382,711 |  | 444,912 |  | 110.23 |  | (9,926 | )
(1) During years 2022, 2023 and 2024, the following individuals served as “principal executive officer” during the time periods set forth below:
|  | Name |  | Dates as PEO During 2022 through 2024
Michael Bristow |  | January 1, 2022 through April 3, 2024
Thomas Keuer |  | April 3, 2024 through August 29, 2024
Dr. Lawrence Klein |  | August 29, 2024 through December 31, 2024
The dollar amounts reported in these columns represent the amount of total compensation reported for each of Drs. Klein and Bristow and Mr. Keuer (collectively, our “PEOs”) for each covered fiscal year in the “Total” column of the Summary Compensation Table for each applicable year. Please refer to “Executive Compensation-Summary Compensation Table” above. (2) The dollar amounts reported in this column represent the average amount of total compensation report for our NEOs as a group (excluding our PEOs) for each covered fiscal year in the “Total” column of the Summary Compensation Table for each applicable year. Please refer to “Executive Compensation-Summary Compensation Table” above. The names of each NEO included for these purposes in each applicable year are as follows:
|  | Year |  | Non-PEO NEOs
2024 |  | Dr. Joana Goncalves, Paul Quinlan, and C. Jeffrey Dekker
2023 |  | Thomas A. Keuer and C. Jeffrey Dekker
2022 |  | Thomas A. Keuer and Christopher D. Ozeroff
(3) The dollar amounts reported in these columns represent the amount of “compensation actually paid” to our PEOs or our NEOs as a group (excluding our PEOs), as computed in accordance with Item 402(v) of Regulation S-K, for each covered fiscal year. In accordance with these rules, these amounts reflect total compensation as set forth in the Summary Compensation Table, adjusted as shown below for 2024. Except as noted below, equity values are calculated in accordance with FASB ASC Topic 718, and the valuation assumptions used to calculate fair values did not materially differ from those disclosed at the time of grant. The dollar amounts do not reflect the actual amount of compensation earned or received by or paid to the PEOs during the applicable fiscal year.
|  |  |  | Dr. Bristow |  | Mr. Keuer |  | Dr. Klein |  | Average Non-PEO NEOs
|  | 2023 |  | 2024 |  | 2024 |  | 2024 |  | 2023 |  | 2024
Summary Compensation Table Total |  | $ | 358,800 |  |  | $ | 510,416 |  |  | $ | 853,520 |  |  | $ | 520,911 |  | $ | 361,937 |  |  | $ | 461,678 |
Less, value of “Stock Awards” and “Option Awards” reported in Summary Compensation Table |  |  | — |  |  | $ | (39,676 | ) |  | $ | (22,484 | ) |  |  | — |  |  | — |  |  | $ | (8,316 | )
Plus, year-end fair value of outstanding and unvested equity awards granted in the year(a) |  |  | — |  |  |  | — |  |  |  | — |  |  | $ | 44,177,373 |  |  | — |  |  | $ | 3,257,026 |
Plus (less), year over year change in fair value of outstanding and unvested equity awards granted in prior years |  | $ | (45,283 | ) |  |  | — |  |  |  | — |  |  |  | — |  | $ | (15,718 | ) |  |  | — |
Plus (less), change in fair value from last day of prior fiscal year to vesting date for equity awards granted in prior years that vested in the year(b) |  | $ | (22,653 | ) |  | $ | 65,304 |  |  | $ | 24,059 |  |  |  | — |  | $ | (22,553 | ) |  | $ | 7,839 |
Less, prior year-end fair value for any equity awards forfeited in the year |  |  | — |  |  | $ | (18,038 | ) |  | $ | (6,642 | ) |  |  | — |  |  | — |  |  |  | — |
Compensation Actually Paid |  | $ | 290,864 |  |  | $ | 518,016 |  |  | $ | 848,453 |  |  | $ | 44,698,284 |  | $ | 323,666 |  |  | $ | 3,718,227 |
(a) For Dr. Klein and the average non-PEO NEOs as a group for 2024, includes the value of awards granted during 2024 by Pre-Merger Oruka that were assumed by the Company in connection with the Merger but that are not reflected in the Summary Compensation Table. (b) For Messrs. Bristow and Keuer and the average non-PEO NEOs as a group for 2024, the value as of the vesting date of the ARCA stock options that were accelerated and cashed out in connection with the Merger is based on the actual cash amount paid (representing the difference between $3.9489 and the applicable per share exercise price). (4) Cumulative total stockholder return (“TSR”) is calculated by dividing (a) the sum of (i) the cumulative amount of dividends during the measurement period, assuming dividend reinvestment, and (ii) the difference between our stock price at the end of the applicable measurement period and the beginning of the measurement period by (b) our stock price at the beginning of the measurement period. The beginning of the measurement period for each year in the table is December 31, 2021. (5) The dollar amounts reported for 2022 and 2023 represent the amount of net income (loss) reflected in ARCA’s audited financial statements for 2022 and 2023. The dollar amount reported for 2024 represents the amount of net income (loss) reflected in our audited financial statements for the period from February 6, 2024 (inception) to December 31, 2024, as reported in our Annual Report on Form 10-K. |  |  |  |  |  |
Named Executive Officers, Footnote |  |  |  | The dollar amounts reported in this column represent the average amount of total compensation report for our NEOs as a group (excluding our PEOs) for each covered fiscal year in the “Total” column of the Summary Compensation Table for each applicable year. Please refer to “Executive Compensation-Summary Compensation Table” above. The names of each NEO included for these purposes in each applicable year are as follows:
|  | Year |  | Non-PEO NEOs
2024 |  | Dr. Joana Goncalves, Paul Quinlan, and C. Jeffrey Dekker
2023 |  | Thomas A. Keuer and C. Jeffrey Dekker
2022 |  | Thomas A. Keuer and Christopher D. Ozeroff
Non-PEO NEO Average Total Compensation Amount | [1] |  |  | $ 461,678 |  | $ 361,937 |  | $ 382,711 |  |
Non-PEO NEO Average Compensation Actually Paid Amount | [2] |  |  | $ 3,718,227 |  | 323,666 |  | 444,912 |  |
Adjustment to Non-PEO NEO Compensation Footnote |  |  |  | The dollar amounts reported in these columns represent the amount of “compensation actually paid” to our PEOs or our NEOs as a group (excluding our PEOs), as computed in accordance with Item 402(v) of Regulation S-K, for each covered fiscal year. In accordance with these rules, these amounts reflect total compensation as set forth in the Summary Compensation Table, adjusted as shown below for 2024. Except as noted below, equity values are calculated in accordance with FASB ASC Topic 718, and the valuation assumptions used to calculate fair values did not materially differ from those disclosed at the time of grant. The dollar amounts do not reflect the actual amount of compensation earned or received by or paid to the PEOs during the applicable fiscal year.
|  |  |  | Dr. Bristow |  | Mr. Keuer |  | Dr. Klein |  | Average Non-PEO NEOs
|  | 2023 |  | 2024 |  | 2024 |  | 2024 |  | 2023 |  | 2024
Summary Compensation Table Total |  | $ | 358,800 |  |  | $ | 510,416 |  |  | $ | 853,520 |  |  | $ | 520,911 |  | $ | 361,937 |  |  | $ | 461,678 |
Less, value of “Stock Awards” and “Option Awards” reported in Summary Compensation Table |  |  | — |  |  | $ | (39,676 | ) |  | $ | (22,484 | ) |  |  | — |  |  | — |  |  | $ | (8,316 | )
Plus, year-end fair value of outstanding and unvested equity awards granted in the year(a) |  |  | — |  |  |  | — |  |  |  | — |  |  | $ | 44,177,373 |  |  | — |  |  | $ | 3,257,026 |
Plus (less), year over year change in fair value of outstanding and unvested equity awards granted in prior years |  | $ | (45,283 | ) |  |  | — |  |  |  | — |  |  |  | — |  | $ | (15,718 | ) |  |  | — |
Plus (less), change in fair value from last day of prior fiscal year to vesting date for equity awards granted in prior years that vested in the year(b) |  | $ | (22,653 | ) |  | $ | 65,304 |  |  | $ | 24,059 |  |  |  | — |  | $ | (22,553 | ) |  | $ | 7,839 |
Less, prior year-end fair value for any equity awards forfeited in the year |  |  | — |  |  | $ | (18,038 | ) |  | $ | (6,642 | ) |  |  | — |  |  | — |  |  |  | — |
Compensation Actually Paid |  | $ | 290,864 |  |  | $ | 518,016 |  |  | $ | 848,453 |  |  | $ | 44,698,284 |  | $ | 323,666 |  |  | $ | 3,718,227 |
(a) For Dr. Klein and the average non-PEO NEOs as a group for 2024, includes the value of awards granted during 2024 by Pre-Merger Oruka that were assumed by the Company in connection with the Merger but that are not reflected in the Summary Compensation Table. (b) For Messrs. Bristow and Keuer and the average non-PEO NEOs as a group for 2024, the value as of the vesting date of the ARCA stock options that were accelerated and cashed out in connection with the Merger is based on the actual cash amount paid (representing the difference between $3.9489 and the applicable per share exercise price). |  |  |  |  |  |
Total Shareholder Return Vs Peer Group |  |  |  | Cumulative total stockholder return (“TSR”) is calculated by dividing (a) the sum of (i) the cumulative amount of dividends during the measurement period, assuming dividend reinvestment, and (ii) the difference between our stock price at the end of the applicable measurement period and the beginning of the measurement period by (b) our stock price at the beginning of the measurement period. The beginning of the measurement period for each year in the table is December 31, 2021. |  |  |  |  |  |
Total Shareholder Return Amount | [3] |  |  | $ 109.89 |  | 79.07 |  | 110.23 |  |
Net Income (Loss) | [4] |  |  | (83,724,000) |  | (5,339,000) |  | (9,926,000) |  |
PEO Name |  | Dr. Lawrence Klein | Thomas Keuer |  |  |  |  |  |  | Michael Bristow
Less, value of “Stock Awards” and “Option Awards” reported in Summary Compensation Table [Member] |  |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |  |  |  |
Adjustment to Compensation, Amount |  |  |  | (8,316) |  |  |  |  |  |
Plus, year-end fair value of outstanding and unvested equity awards granted in the year [Member] |  |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |  |  |  |
Adjustment to Compensation, Amount | [5] |  |  | 3,257,026 |  |  |  |  |  |
Plus (less), year over year change in fair value of outstanding and unvested equity awards granted in prior years [Member] |  |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |  |  |  |
Adjustment to Compensation, Amount |  |  |  |  |  | (15,718) |  |  |  |
Plus (less), change in fair value from last day of prior fiscal year to vesting date for equity awards granted in prior years that vested in the year [Member] |  |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |  |  |  |
Adjustment to Compensation, Amount | [6] |  |  | 7,839 |  | (22,553) |  |  |  |
Less, prior year-end fair value for any equity awards forfeited in the year [Member] |  |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |  |  |  |
Adjustment to Compensation, Amount |  |  |  |  |  |  |  |  |  |
Mr. Bristow [Member] |  |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |  |  |  |
PEO Total Compensation Amount | [7] |  |  | 510,416 |  | 358,800 |  | 358,800 |  |
Mr. Keuer [Member] |  |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |  |  |  |
PEO Total Compensation Amount | [7] |  |  | 853,520 |  |  |  |  |  |
PEO Actually Paid Compensation Amount | [2] |  |  | 848,453 |  |  |  |  |  |
Mr. Keuer [Member] | Less, value of “Stock Awards” and “Option Awards” reported in Summary Compensation Table [Member] |  |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |  |  |  |
Adjustment to Compensation, Amount |  |  |  | (22,484) |  |  |  |  |  |
Mr. Keuer [Member] | Plus, year-end fair value of outstanding and unvested equity awards granted in the year [Member] |  |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |  |  |  |
Adjustment to Compensation, Amount | [5] |  |  |  |  |  |  |  |  |
Mr. Keuer [Member] | Plus (less), year over year change in fair value of outstanding and unvested equity awards granted in prior years [Member] |  |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |  |  |  |
Adjustment to Compensation, Amount |  |  |  |  |  |  |  |  |  |
Mr. Keuer [Member] | Plus (less), change in fair value from last day of prior fiscal year to vesting date for equity awards granted in prior years that vested in the year [Member] |  |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |  |  |  |
Adjustment to Compensation, Amount | [6] |  |  | 24,059 |  |  |  |  |  |
Mr. Keuer [Member] | Less, prior year-end fair value for any equity awards forfeited in the year [Member] |  |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |  |  |  |
Adjustment to Compensation, Amount |  |  |  | (6,642) |  |  |  |  |  |
Dr. Klein [Member] |  |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |  |  |  |
PEO Total Compensation Amount | [7] |  |  | 520,911 |  |  |  |  |  |
PEO Actually Paid Compensation Amount |  |  |  | 44,698,284 | [2] |  | [7] |  | [2] |
Dr. Klein [Member] | Less, value of “Stock Awards” and “Option Awards” reported in Summary Compensation Table [Member] |  |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |  |  |  |
Adjustment to Compensation, Amount |  |  |  |  |  |  |  |  |  |
Dr. Klein [Member] | Plus, year-end fair value of outstanding and unvested equity awards granted in the year [Member] |  |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |  |  |  |
Adjustment to Compensation, Amount | [5] |  |  | 44,177,373 |  |  |  |  |  |
Dr. Klein [Member] | Plus (less), year over year change in fair value of outstanding and unvested equity awards granted in prior years [Member] |  |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |  |  |  |
Adjustment to Compensation, Amount |  |  |  |  |  |  |  |  |  |
Dr. Klein [Member] | Plus (less), change in fair value from last day of prior fiscal year to vesting date for equity awards granted in prior years that vested in the year [Member] |  |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |  |  |  |
Adjustment to Compensation, Amount | [6] |  |  |  |  |  |  |  |  |
Dr. Klein [Member] | Less, prior year-end fair value for any equity awards forfeited in the year [Member] |  |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |  |  |  |
Adjustment to Compensation, Amount |  |  |  |  |  |  |  |  |  |
Dr. Bristow [Member] |  |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |  |  |  |
PEO Total Compensation Amount |  |  |  | 510,416 |  | 358,800 |  |  |  |
PEO Actually Paid Compensation Amount | [2] |  |  | 518,016 |  | 290,864 |  | $ 523,780 |  |
Dr. Bristow [Member] | Less, value of “Stock Awards” and “Option Awards” reported in Summary Compensation Table [Member] |  |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |  |  |  |
Adjustment to Compensation, Amount |  |  |  | (39,676) |  |  |  |  |  |
Dr. Bristow [Member] | Plus, year-end fair value of outstanding and unvested equity awards granted in the year [Member] |  |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |  |  |  |
Adjustment to Compensation, Amount | [5] |  |  |  |  |  |  |  |  |
Dr. Bristow [Member] | Plus (less), year over year change in fair value of outstanding and unvested equity awards granted in prior years [Member] |  |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |  |  |  |
Adjustment to Compensation, Amount |  |  |  |  |  | (45,283) |  |  |  |
Dr. Bristow [Member] | Plus (less), change in fair value from last day of prior fiscal year to vesting date for equity awards granted in prior years that vested in the year [Member] |  |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |  |  |  |
Adjustment to Compensation, Amount | [6] |  |  | 65,304 |  | (22,653) |  |  |  |
Dr. Bristow [Member] | Less, prior year-end fair value for any equity awards forfeited in the year [Member] |  |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |  |  |  |
Adjustment to Compensation, Amount |  |  |  | $ (18,038) |  |  |  |  |  |
[1] | The dollar amounts reported in this column represent the average amount of total compensation report for our NEOs as a group (excluding our PEOs) for each covered fiscal year in the “Total” column of the Summary Compensation Table for each applicable year. Please refer to “Executive Compensation-Summary Compensation Table” above. The names of each NEO included for these purposes in each applicable year are as follows:
|  | Year |  | Non-PEO NEOs
2024 |  | Dr. Joana Goncalves, Paul Quinlan, and C. Jeffrey Dekker
2023 |  | Thomas A. Keuer and C. Jeffrey Dekker
2022 |  | Thomas A. Keuer and Christopher D. Ozeroff
[2] | The dollar amounts reported in these columns represent the amount of “compensation actually paid” to our PEOs or our NEOs as a group (excluding our PEOs), as computed in accordance with Item 402(v) of Regulation S-K, for each covered fiscal year. In accordance with these rules, these amounts reflect total compensation as set forth in the Summary Compensation Table, adjusted as shown below for 2024. Except as noted below, equity values are calculated in accordance with FASB ASC Topic 718, and the valuation assumptions used to calculate fair values did not materially differ from those disclosed at the time of grant. The dollar amounts do not reflect the actual amount of compensation earned or received by or paid to the PEOs during the applicable fiscal year.
|  |  |  | Dr. Bristow |  | Mr. Keuer |  | Dr. Klein |  | Average Non-PEO NEOs
|  | 2023 |  | 2024 |  | 2024 |  | 2024 |  | 2023 |  | 2024
Summary Compensation Table Total |  | $ | 358,800 |  |  | $ | 510,416 |  |  | $ | 853,520 |  |  | $ | 520,911 |  | $ | 361,937 |  |  | $ | 461,678 |
Less, value of “Stock Awards” and “Option Awards” reported in Summary Compensation Table |  |  | — |  |  | $ | (39,676 | ) |  | $ | (22,484 | ) |  |  | — |  |  | — |  |  | $ | (8,316 | )
Plus, year-end fair value of outstanding and unvested equity awards granted in the year(a) |  |  | — |  |  |  | — |  |  |  | — |  |  | $ | 44,177,373 |  |  | — |  |  | $ | 3,257,026 |
Plus (less), year over year change in fair value of outstanding and unvested equity awards granted in prior years |  | $ | (45,283 | ) |  |  | — |  |  |  | — |  |  |  | — |  | $ | (15,718 | ) |  |  | — |
Plus (less), change in fair value from last day of prior fiscal year to vesting date for equity awards granted in prior years that vested in the year(b) |  | $ | (22,653 | ) |  | $ | 65,304 |  |  | $ | 24,059 |  |  |  | — |  | $ | (22,553 | ) |  | $ | 7,839 |
Less, prior year-end fair value for any equity awards forfeited in the year |  |  | — |  |  | $ | (18,038 | ) |  | $ | (6,642 | ) |  |  | — |  |  | — |  |  |  | — |
Compensation Actually Paid |  | $ | 290,864 |  |  | $ | 518,016 |  |  | $ | 848,453 |  |  | $ | 44,698,284 |  | $ | 323,666 |  |  | $ | 3,718,227 |
(a) For Dr. Klein and the average non-PEO NEOs as a group for 2024, includes the value of awards granted during 2024 by Pre-Merger Oruka that were assumed by the Company in connection with the Merger but that are not reflected in the Summary Compensation Table. (b) For Messrs. Bristow and Keuer and the average non-PEO NEOs as a group for 2024, the value as of the vesting date of the ARCA stock options that were accelerated and cashed out in connection with the Merger is based on the actual cash amount paid (representing the difference between $3.9489 and the applicable per share exercise price).
[3] | Cumulative total stockholder return (“TSR”) is calculated by dividing (a) the sum of (i) the cumulative amount of dividends during the measurement period, assuming dividend reinvestment, and (ii) the difference between our stock price at the end of the applicable measurement period and the beginning of the measurement period by (b) our stock price at the beginning of the measurement period. The beginning of the measurement period for each year in the table is December 31, 2021.
[4] | The dollar amounts reported for 2022 and 2023 represent the amount of net income (loss) reflected in ARCA’s audited financial statements for 2022 and 2023. The dollar amount reported for 2024 represents the amount of net income (loss) reflected in our audited financial statements for the period from February 6, 2024 (inception) to December 31, 2024, as reported in our Annual Report on Form 10-K.
[5] | For Dr. Klein and the average non-PEO NEOs as a group for 2024, includes the value of awards granted during 2024 by Pre-Merger Oruka that were assumed by the Company in connection with the Merger but that are not reflected in the Summary Compensation Table.
[6] | For Messrs. Bristow and Keuer and the average non-PEO NEOs as a group for 2024, the value as of the vesting date of the ARCA stock options that were accelerated and cashed out in connection with the Merger is based on the actual cash amount paid (representing the difference between $3.9489 and the applicable per share exercise price).
[7] | During years 2022, 2023 and 2024, the following individuals served as “principal executive officer” during the time periods set forth below:
|  | Name |  | Dates as PEO During 2022 through 2024
Michael Bristow |  | January 1, 2022 through April 3, 2024
Thomas Keuer |  | April 3, 2024 through August 29, 2024
Dr. Lawrence Klein |  | August 29, 2024 through December 31, 2024
The dollar amounts reported in these columns represent the amount of total compensation reported for each of Drs. Klein and Bristow and Mr. Keuer (collectively, our “PEOs”) for each covered fiscal year in the “Total” column of the Summary Compensation Table for each applicable year. Please refer to “Executive Compensation-Summary Compensation Table” above.

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToNonPeoNeoCompFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_NamedExecutiveOfficersFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iii + Details
Name: | ecd_NonPeoNeoAvgCompActuallyPaidAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph ii + Details
Name: | ecd_NonPeoNeoAvgTotalCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iii + Details
Name: | ecd_PeoActuallyPaidCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_PeoName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph ii + Details
Name: | ecd_PeoTotalCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details
Name: | ecd_PvpTable
Namespace Prefix: | ecd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details
Name: | ecd_PvpTableTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_TotalShareholderRtnAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph iv + Details
Name: | ecd_TotalShareholderRtnVsPeerGroupTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4 Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7 Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details
Name: | us-gaap_NetIncomeLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ecd_AdjToCompAxis=orka_LessValueOfStockAwardsAndOptionAwardsReportedInSummaryCompensationTableMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=orka_PlusYearendFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=orka_PluslessYearOverYearChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorYearsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=orka_PluslessChangeInFairValueFromLastDayOfPriorFiscalYearToVestingDateForEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=orka_LessPriorYearendFairValueForAnyEquityAwardsForfeitedInTheYearMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_IndividualAxis=orka_MrBristowMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_IndividualAxis=orka_MrKeuerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_IndividualAxis=orka_DrKleinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_IndividualAxis=orka_DrBristowMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |